Levetiracetam vs. phenobarbitone in neonatal seizures - a randomised controlled trial at a tertiary care hospital in Southern Rajasthan
DOI:
https://doi.org/10.18203/2349-3291.ijcp20253485Keywords:
Hypoxic-ischemic encephalopathy, Levetiracetam, Neonatal seizures, PhenobarbitoneAbstract
Background: Neonatal seizures, most commonly due to hypoxic-ischemic encephalopathy (HIE), represent a medical emergency with substantial morbidity. While phenobarbitone (PB) remains the first-line antiepileptic, its efficacy varies and adverse effects are frequent. Levetiracetam (LEV) may offer a safer and equally effective alternative.
Methods: In this randomized controlled trial conducted at RNT Medical College NICU, Udaipur, 120 EEG-confirmed neonatal seizure cases were randomized equally to receive either LEV or PB. Seizure control within 24 hours without switching was the primary outcome; secondary outcomes included drug switching, adverse events, discharge rate and mortality.
Results: Baseline characteristics were well-matched between groups. Initial seizure control was achieved in 81.6% of the LEV group and 71.6% of the PB group (p=0.195). After switching, seizure control rates significantly favored LEV over PB (96.7% vs 86.7%, p=0.048). Adverse events occurred in 11.7% of neonates receiving LEV versus 23.3% with PB (p=0.036). No significant difference was observed in mortality or discharge rates between the two groups.
Conclusions: Levetiracetam demonstrated a comparable efficacy to phenobarbitone in neonatal seizure control, with a significantly better safety profile and higher effectiveness after drug switching. LEV shows promise as a preferable first-line or adjunctive therapy for neonatal seizures.
Metrics
References
Spagnoli C, Falsaperla R, Deolmi M. Symptomatic seizures in preterm newborns: a review on clinical features and prognosis. Ital J Pediatr. 2018;44(1):115. DOI: https://doi.org/10.1186/s13052-018-0573-y
Singh M. Neurological disorders. In: Singh M, ed. Care of the Newborn. 8th ed. New Delhi: CBS Publishers & Distributors; 2017: 435-437.
Tekgul H, Gauvreau K, Soul J, Murphy L, Robertson R, Stewart J, et al. The current etiologic profile and neurodevelopmental outcome of seizures in term newborn infants. Pediatrics. 2006;117(4):1270-80. DOI: https://doi.org/10.1542/peds.2005-1178
Van Rooij LG, Hellström-Westas L, de Vries LS. Treatment of neonatal seizures. Semin Fetal Neonatal Med. 2013;18:209-15. DOI: https://doi.org/10.1016/j.siny.2013.01.001
Han JY, Moon CJ, Youn YA, Sung IK, Lee IG. Efficacy of levetiracetam for neonatal seizures in preterm infants. BMC Pediatr. 2018;18:131. DOI: https://doi.org/10.1186/s12887-018-1103-1
Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord. 2007;9:353-412. DOI: https://doi.org/10.1684/epd.2007.0144
Tripathi KD. Anti-epileptic drugs. In: Essentials of Medical Pharmacology. 7th ed. New Delhi: Jaypee Brothers Medical Publishers; 2013:443-445.
Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999;341:485-9. DOI: https://doi.org/10.1056/NEJM199908123410704
Manthey D, Asimiadou S, Stefovska V, Kaindl AM, Fassbender J, Ikonomidou C, et al. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol. 2005;193:497-503. DOI: https://doi.org/10.1016/j.expneurol.2005.01.006
Venkatesan C, Young S, Schapiro M, Thomas C. Levetiracetam for the treatment of seizures in neonatal hypoxic ischemic encephalopathy. J Child Neurol. 2017;32:210-4. DOI: https://doi.org/10.1177/0883073816678102
Pina-Garza JE, Nordli DR, Jr, Rating D, Yang H, Schiemann-Delgado J, Duncan B. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia. 2009;50(5):1141–9. DOI: https://doi.org/10.1111/j.1528-1167.2008.01981.x
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–63. DOI: https://doi.org/10.1111/epi.12074
Silverstein FS, Ferriero DM. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol. 2008;39:77-9. DOI: https://doi.org/10.1016/j.pediatrneurol.2008.04.008
Abend NS, Gutierrez-Colina AM, Monk HM, Dlugos DJ, Clancy RR. Levetiracetam for treatment of neonatal seizures. J Child Neurol. 2011;26:465-70. DOI: https://doi.org/10.1177/0883073810384263
Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861–6. DOI: https://doi.org/10.1073/pnas.0308208101
Lima-Rogel V, López-López EJ, Medellín-Garibay SE, Gómez-Ruiz LM, Romero-Méndez C, Milán-Segovia RC, et al. Population pharmacokinetics of levetiracaetam in neonates with seizures. J Clin Pharm Ther. 2018;43:422-9. DOI: https://doi.org/10.1111/jcpt.12658
Pacifici GM. Clinical pharmacology of phenobarbital in neonates: effects, metabolism and pharmacokinetics. Curr Pediatr Rev. 2016;12:48-54. DOI: https://doi.org/10.2174/1573397111666151026223914
Bättig L, Dünner C, Cserpan D, Rüegger A, Hagmann C, Schmitt B, et al. Levetiracetam versus Phenobarbital for Neonatal Seizures: A Retrospective Cohort Study. Pediatr Neurol. 2023;138:62-70. DOI: https://doi.org/10.1016/j.pediatrneurol.2022.10.004
Gowda VK, Romana A, Shivanna NH, Benakappa N, Benakappa A. Levetiracetam versus phenobarbitone in neonatal seizures: a randomized controlled trial. Indian Pediatr 2019;56:643-6. DOI: https://doi.org/10.1007/s13312-019-1586-3
Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol. 2011;15:1-7. DOI: https://doi.org/10.1016/j.ejpn.2010.10.003
Khan O, Cipriani C, Wright C, Crisp E, Kirmani B. Role of intravenous levetiracetam for acute seizure management in preterm neonates. Pediatr Neurol. 2013;49:340-3. DOI: https://doi.org/10.1016/j.pediatrneurol.2013.05.008
Sharpe C, Reiner GE, Davis SL, Nespeca M, Gold JJ, Rasmussen M, et al. NEOLEV2 INVESTIGATORS. Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial. Pediatrics. 2020;145(6):20193182. DOI: https://doi.org/10.1542/peds.2019-3182
Gyandeep G, Behura SS, Sahu SK, Panda SK. Comparison between phenobarbitone and levetiracetam as the initial anticonvulsant in preterm neonatal seizures: a pilot randomized control trial in developing country setup. Eur J Pediatr. 2023;182:2133-8. DOI: https://doi.org/10.1007/s00431-023-04864-x
Toptan HH, Karadag NN, Topcuoglu S, Ozalkaya E, Dincer E, Cakir H, et al. Comparative Outcomes of Levetiracetam and Phenobarbital Usage in the Treatment of Neonatal Seizures: A Retrospective Analysis. Healthcare (Basel). 2024;12(7):800. DOI: https://doi.org/10.3390/healthcare12070800
Kreimer AM, Littrell RA, Gibson JB, Leung NR. Effectiveness of levetiracetam as a first-line anticonvulsant for neonatal seizures. J Pediatr Pharmacol Ther. 2019;24:320-6. DOI: https://doi.org/10.5863/1551-6776-24.4.320
Susnerwala S, Joshi A, Deshmukh L, Londhe A. Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hosp Pediatr. 2022;12:647-53. DOI: https://doi.org/10.1542/hpeds.2021-006415
Downloads
Published
How to Cite
Issue
Section
